Engflag

Dhasedyl

Quick links to important sections

Dhasedyl

Dhasedyl_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dhasedyl

Property Description
Active Ingredient Codeine, Ephedrine, Promethazine
Form Oral Solution (Syrup/Linctus)
Pharmacological Class Combination Upper Respiratory Agent
General Purpose Symptomatic relief of cough and congestion
Origin Semi-synthetic and Synthetic Compounds

Dhasedyl is an oral pharmaceutical preparation known as a fixed-dose combination product, specifically formulated as a Syrup or Oral Solution. It is composed of three distinct active ingredients—Codeine, Ephedrine, and Promethazine—which work together to provide comprehensive symptomatic relief for acute respiratory conditions.

Composition, Class, and Differentiation

Dhasedyl is classified as a combination drug because it integrates agents from three separate pharmacological classes. The composition includes Codeine Phosphate, an opioid derivative that serves as a central antitussive, an effect long clinically recognized for controlling persistent coughs. Ephedrine Hydrochloride provides a sympathomimetic action for decongestion, while Promethazine Hydrochloride functions as a first-generation H1 Receptor Antihistamine.

Its distinguishing feature is the specific three-way combination which offers a unique pharmacological profile: the sedating antihistamine Promethazine and the potent opioid antitussive Codeine deliver robust central symptom control, differentiating it from formulations containing non-sedating antihistamines or non-narcotic cough suppressants. The official pharmacological categorization of Codeine emphasizes its primary action on the central cough center. This confirms the medication's intended effect is to reduce the urge and frequency of coughing.

Form and Administration Type

The pharmaceutical presentation of Dhasedyl is an Oral Solution, commonly marketed as a Syrup or Linctus, and is administered exclusively via the oral route. The liquid form, characterized by an aqueous vehicle, is easily measurable and is a practical choice for patients needing relief from irritated throats. This liquid dosage form is beneficial in typical use scenarios involving short-term management of common cold or flu symptoms where both cough and upper airway congestion are present.

What side effects are possible with Dhasedyl?

Possible Side Effects and Safety Information

The safety profile for this combination product (containing Codeine, Ephedrine, and Promethazine) is structured based on explicit adverse reactions and regulatory constraints documented by government health authorities, such as the U.S. Food and Drug Administration (FDA).

Common Adverse Reactions

Adverse effects listed as common in official labeling primarily affect the nervous and gastrointestinal systems. These include sedation (such as somnolence, mental clouding, and lethargy), lightheadedness, dizziness, headache, and impaired mental or physical performance. Gastrointestinal effects such as dry mouth, nausea, vomiting, and constipation are also commonly documented. Other general effects reported are shortness of breath and sweating.

Documented Serious Adverse Reactions

Official documents emphasize the potential for serious reactions, including life-threatening respiratory depression, a risk that requires close monitoring, especially during the initiation of therapy or following a dosage increase. Other serious documented risks include severe hypotension, Neuroleptic Malignant Syndrome (NMS), seizures, and risks associated with the opioid component such as Adrenal Insufficiency and Addiction, Abuse, and Misuse.

Population-Specific Safety Constraints

The product is contraindicated in children younger than 12 years of age. It is also contraindicated in adolescents younger than 18 years following tonsillectomy and/or adenoidectomy. Use in pregnant women may cause fetal harm, and breastfeeding is not recommended. Caution is advised when used in older adults and in patients with severe renal or hepatic impairment.

Resulting Safety Structure

The regulatory safety profile highlights the high probability of CNS-related and gastrointestinal adverse reactions while underscoring the serious, but less frequent, risks of respiratory depression and NMS as core regulatory warnings. The framework defines specific population restrictions, thereby formally limiting the conditions and groups where the medicine may be considered.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Dhasedyl, a combination product, may present with a spectrum of symptoms reflecting the toxicity of its three active ingredients, as documented in official prescribing information.

Documented Manifestations Official regulatory sources list severe central nervous system (CNS) depression, ranging from profound somnolence to coma. Life-threatening respiratory depression is the most serious consequence, which can lead to death. Other documented signs include seizures, miosis (pinpoint pupils), tachycardia, and hypertension due to the sympathomimetic component. Severe outcomes also include the risk of Neuroleptic Malignant Syndrome and cardiac arrhythmias.

Emergency Actions Required The labeling mandates that patients seek immediate medical attention for any suspected overdose. Emergency services must be contacted immediately if symptoms such as trouble breathing, shallow breathing, or unresponsiveness occur. Management involves symptomatic and supportive treatment. The specific opioid antagonist Naloxone is available for reversing respiratory depression caused by the codeine component.

Population Considerations A heightened risk of fatal overdose is noted for children due to accidental ingestion. Patients identified as ultra-rapid metabolizers of Codeine are also at increased risk for life-threatening respiratory depression. Close monitoring is required for all patients, especially those who are elderly or have severe renal or hepatic impairment.

Therapeutic Uses of Dhasedyl

What Dhasedyl Treats: Main Uses and Benefits

Dhasedyl is commonly used across conditions presenting with acute, episodic, or fluctuating symptom patterns, such as the common cold, symptomatic bronchitis, or acute allergy flares. The combination is considered relevant when supportive symptom management is appropriate for the temporary relief of cough and upper respiratory symptoms associated with allergy or the common cold. It is applied in clinical settings marked by heightened patient distress and may provide supportive relief that assists patients in coping with difficult episodes, contributing to a more manageable experience during acute phases.

The medication is specifically applied in addressing symptom clusters associated with a persistent, non-productive cough, nasal congestion, runny nose (rhinorrhea), and sneezing. It is commonly used to help ease the overall symptom burden of the distressing cough and provides supportive relief when these symptoms interfere with rest.

“Dhasedyl may assist in easing distress during difficult episodes and is commonly used when short-term symptomatic assistance is needed.”

Clinical Focus: Support for Combined Upper Respiratory Symptoms

Therapeutic Focus

This medication is applied in addressing symptoms that become more disruptive during flare-ups. It contributes to improved day-to-day comfort by helping address the physical discomfort of blocked airways and excessive nasal discharge, and may assist with maintaining functional stability during symptomatic periods.

Eligibility and Restrictions for Use

The eligibility profile for Dhasedyl is defined by specific regulatory constraints based on age, physiological status, and metabolic capacity. The medicine is primarily indicated for use in adults 18 years of age and older who do not have any contraindicating health conditions.

Absolute Contraindications

Dhasedyl must not be used by any patient under 12 years of age. Use is strictly prohibited in breastfeeding women and individuals known to be CYP2D6 ultra-rapid metabolizers. Further contraindications include patients with severe respiratory depression, acute bronchial asthma, or those in a comatose state. Patients who have recently undergone a tonsillectomy or adenoidectomy (under 18 years) or who are taking a Monoamine Oxidase Inhibitor (MAOI) must also avoid use. The medicine is contraindicated for treatment of lower respiratory tract symptoms.

Restricted and Conditional Use

Use is generally avoided in adolescents aged 12 to 18 who present with risk factors such as obstructive sleep apnea or obesity. The official label requires special caution for geriatric patients and individuals with severe hepatic or renal impairment. Pregnant women are not recommended to use the medicine due to the risk of Neonatal Opioid Withdrawal Syndrome with prolonged exposure.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Dhasedyl (Codeine, Ephedrine, Promethazine) is defined by its components' combined risks documented in governmental regulatory labeling. Interactions are primarily classified into pharmacodynamic and pharmacokinetic effects, dictating restrictions and required separations.

Contraindicated and High-Risk Combinations

  • Monoamine Oxidase Inhibitors (MAOIs): Co-administration is formally contraindicated, and use must be separated by at least 14 days. This rule addresses the risk of pressor augmentation and excessive CNS effects.
  • CNS Depressants and Alcohol: Concomitant use with alcohol, benzodiazepines, and other CNS depressants is strictly avoided due to the officially stated risk of profound sedation, respiratory depression, coma, and death.

Metabolic and Pharmacodynamic Interactions

  • CYP Inhibitors/Inducers: Co-administration with strong CYP2D6 and CYP3A4 inhibitors or inducers must be avoided. These substances alter the official metabolic pathway of Codeine, modifying its systemic exposure and the formation of its active metabolite.
  • Anticholinergics and Serotonergic Drugs: Use with other anticholinergics increases the risk of additive effects, such as paralytic ileus. The opioid component (Codeine) requires caution with serotonergic drugs due to the documented risk of serotonin syndrome.

Population Note: Regulatory documents note that effects may be increased in patients with Hepatic Impairment due to slower clearance, which can intensify interaction consequences.

Mechanism of Action

Central Modulation of the Cough Reflex Arc

The core mechanism for dampening the cough reflex involves Codeine acting as an agonist on mu-Opioid Receptors within the brainstem's medullary cough center. This action initiates an inhibitory cellular cascade that dampens neuronal excitability, fundamentally modulating the transmission of the efferent signal originating from the central cough center.

Autonomic Airway Structural and Secretion Control

Airway structure and output are modulated by the combined action of Ephedrine and Promethazine on the autonomic system. Ephedrine triggers the release of Norepinephrine, activating alpha1-adrenergic receptors to cause localized vasoconstriction in nasal capillaries, physically decreasing fluid extravasation and reducing the volume of the nasal mucosa. Concurrently, Promethazine blocks Muscarinic Acetylcholine Receptors (mAChR), leading to an inhibition of glandular secretion output (serous and mucous discharge).

Histaminergic Blockade and Central Nervous System Depression

This domain is driven by Promethazine, a first-generation Histamine H1 receptor antagonist with high affinity for the central receptor. This action blocks histamine binding at peripheral receptors, inhibiting histamine-mediated increases in vascular permeability. Its ability to cross the blood-brain barrier facilitates strong central H1 receptor blockade. This results in central nervous system depression, a primary physiological consequence of H1 receptor blockade.

Synergistic Mechanistic Enhancement

The combination engages complementary mechanisms: the CNS depression from Promethazine functionally contributes to the antitussive central control from Codeine, while the anticholinergic drying effect of Promethazine complements the vasoconstrictive decongestion of Ephedrine, resulting in a combined, multi-pathway modulation of central and peripheral physiological processes.

Dosage and Administration Information

How to Use Dhasedyl

Dhasedyl is exclusively administered via the oral route, as it is formulated as an Oral Solution or Syrup. The product is intended for as-needed (PRN) use to address acute respiratory symptoms, and official instructions strictly define the parameters for its administration, dosage, and duration.

Official Administration Guidelines

Parameter Official Regulatory Instruction
Route of Administration Oral route only.
Dosing Schedule (Adults) Unit dose is 5 mL of the oral solution. The total dose must not exceed 30 mL in a 24-hour period.
Frequency Doses are separated by an interval of 4 to 6 hours, taken only as needed for symptoms.
Duration Principle Must be used for the shortest possible duration consistent with treatment goals.
Age Restriction Not indicated for use in patients under 18 years of age.

Procedural and Course Constraints

Official labeling mandates that the solution be measured precisely using an accurate milliliter measuring device to ensure the correct dosage volume is administered. The procedural constraints are clear: if the cough fails to respond to the standard 5 mL dose, the dose or frequency must not be increased. Furthermore, patients whose cough remains unresponsive must be clinically reevaluated in 5 days or sooner, establishing a short, time-bound limit on the course of use. Special caution is also required for administration to adults with severe renal or hepatic impairment.

The overall use protocol is designed around a strictly measured, short-term, symptom-contingent regimen, emphasizing that the medication's use should be discontinued if the defined dosing parameters are ineffective within a short period.

Recent Clinical Evidence

Dhasedyl: Recent Clinical Evidence

Dhasedyl is a prescription medication combining codeine (an opioid antitussive) and promethazine (a first-generation antihistamine). Its active ingredients are used to provide temporary relief of cough and upper respiratory symptoms associated with the common cold or allergies. Clinical understanding of this combination largely focuses on the safety profiles and the efficacy of its components, particularly the opioid codeine.

Efficacy and Antitussive Action

Codeine has historically been considered a standard cough suppressant, acting centrally in the brain to decrease the urge to cough. However, some recent placebo-controlled studies have challenged this long-held view, finding that codeine may be no more effective than placebo in suppressing certain types of cough, such as those caused by upper respiratory disorders or chronic obstructive pulmonary disease. The antitussive effect of the combination is often seen as variable, and an unresponsive cough warrants a medical re-evaluation to rule out a more serious underlying pathology.

Safety and Regulatory Warnings

Recent regulatory actions and post-marketing data have led to strengthened warnings regarding the combination, primarily due to the serious risks associated with codeine. This includes the potential for life-threatening respiratory depression and opioid-related adverse effects.

Key safety considerations that have been highlighted include:

  • Pediatric Contraindication: The combination is contraindicated in children younger than 12 years of age, and in adolescents following tonsillectomy or adenoidectomy, due to the risk of ultra-rapid metabolism of codeine to morphine.
  • Central Nervous System (CNS) Depression: The sedative effects of both codeine and promethazine are significant, and concurrent use with other CNS depressants, including alcohol or benzodiazepines, can lead to profound sedation, respiratory depression, coma, and death.
  • Abuse and Misuse: The prescription status of this product is maintained due to the high risk of opioid dependence, abuse, and misuse. Prescribing guidelines emphasize using the lowest effective dose for the shortest necessary duration.

Key Studies & References

  1. Medications Containing Low-Dose Codeine for the Treatment of Pain and Coughs - Canadian Agency for Drugs and Technologies in Health (CADTH) Review
  2. Promethazine HCl and Codeine Phosphate Oral Solution - DailyMed (NIH/NLM)

Frequently Asked Questions (FAQ)

Common questions about Dhasedyl (FAQ)

Q: What is Dhasedyl used for?

Dhasedyl is classified as an antispasmodic medication. According to official product information, it is indicated for relieving symptoms associated with various conditions, including irritable bowel syndrome (IBS) and other functional gastrointestinal disorders. Its intended role is to assist in relaxing the smooth muscles of the digestive tract.

Q: Can Dhasedyl be taken with or without food?

Regulatory documents state that Dhasedyl is generally recommended to be taken just before meals. This timing is advised to support the drug's intended action as food is being digested. Instructions on taking it with food are detailed in the official product information.

Q: What happens if I miss a dose of Dhasedyl?

If a dose is forgotten, the official product information advises skipping the missed dose. The recommended approach is to continue with the next scheduled dose at the regular time. Regulatory warnings state that a double dose should not be taken to compensate for a missed dose.

Q: How long does it take for Dhasedyl to start working?

The mechanism of action for Dhasedyl involves targeting the smooth muscle of the gut wall. The drug is indicated for the relief of spasms and pain. Label information suggests it acts on the smooth muscle; however, details on the expected time frame are available in the official product information.

Q: Is it safe to drive or operate machinery while taking Dhasedyl?

According to the official product information, Dhasedyl is generally not expected to impair the ability to drive or operate machinery. The official warning advises exercising caution if known side effects, such as dizziness or drowsiness, occur.

How should Dhasedyl be stored and disposed of?

Storing Dhasedyl

Dhasedyl (promethazine/dextromethorphan/ephedrine) should be stored at room temperature, typically between 68 F and 77 F (20 C and 25 C), away from direct light, heat, and moisture. Do not store this medication in the bathroom. Ensure the bottle is tightly capped. Keep all medications out of the sight and reach of children and pets.

Disposing of Dhasedyl

To dispose of Dhasedyl safely, follow any specific instructions provided by your pharmacist or local drug take-back program. Do not flush this medication down the toilet or pour it down a drain unless specifically instructed to do so by a healthcare professional or a medication guide. When no take-back program is available, mix the medication with an undesirable substance (like cat litter or coffee grounds), place it in a sealed bag or container, and discard it in your regular trash to prevent accidental ingestion.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagHong Kong

flagSingapore

Equivalent of Dhasedyl found in:

A-Z Index: